Maciej Drożdż
Advisor Lukasiewicz - PORT
Seminars
Wednesday 28th January 2026
Panel Discussion: De-Risking mRNA Innovation to Attract Investment & Partnerships in a Post-Vaccine Era
4:00 pm
- What makes an mRNA therapeutic platform fundable in 2026? What clinical and strategic proof do VCs want to see?
- How are biotech leaders navigating delivery licensing limitations, high COGS, and regulatory uncertainty to stay attractive to partners?
- Are non-US trial strategies, earlier pharma engagement, or new reimbursement models the key to investor re-engagement?
Tuesday 27th January 2026
From Vaccines to Vision: Unlocking mRNA’s Next Clinical Success
12:00 pm
- Learning from vaccines: Exploring how mRNA’s transient biology is not a drawback but an asset
- Building on innovation: Reviewing how advances in mRNA topologies, stability, and delivery systems are expanding what mRNA can achieve
- Why Ophthalmology?: Discussing how eye diseases demand localized, adjustable, and repeatable therapies, exactly where transient, programmable mRNA expression can deliver disease-modifying therapies or cures
